Microgeste

Ethinylestradiol and Gestodene, the active ingredients in Microgeste, are a combined oral contraceptive presented as a tablet for oral use. They prevent pregnancy by suppressing ovulation and altering cervical mucus in women of reproductive age.

GNH USA supplies Microgeste as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Microgeste is a combined hormonal contraceptive indicated for preventing pregnancy in women of child‑bearing potential.

- Contraception: provides reliable hormonal birth control to prevent unintended pregnancy. - Family planning: offers a reversible method for women seeking long‑term pregnancy prevention. - Menstrual regulation: helps maintain a regular menstrual cycle while on therapy.

Microgeste may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: intermittent mild to moderate pain. - Spotting: irregular vaginal bleeding between periods. - Mood changes: fluctuations in emotional state. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in the legs. - Pulmonary embolism: clot migration to the lungs. - Stroke: cerebrovascular accident due to clotting. - Myocardial infarction: heart attack risk. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver tumor: rare hepatic neoplasm.

Before prescribing Microgeste, clinicians should consider several safety aspects.

- Assess thrombotic risk: evaluate personal and family history of clotting disorders. - Avoid smoking: especially in women over 35 years of age. - Monitor blood pressure: hypertension may increase cardiovascular risk. - Review liver function: hepatic impairment can alter drug metabolism. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Microgeste can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong enzyme inducers (e.g., rifampin, carbamazepine): may reduce contraceptive effectiveness. - Certain antiretrovirals (e.g., efavirenz): can lower hormone levels and increase failure risk. - Additional hormonal therapy (e.g., estrogen replacement): may heighten thrombosis risk.

Moderate Interactions (Monitor Closely): - Some antibiotics (e.g., tetracycline): may slightly diminish contraceptive efficacy. - Antihypertensives (e.g., ACE inhibitors): may affect blood pressure control. - Herbal supplements (e.g., St. John’s wort): can lower hormone concentrations.